Table 6. Interactions among NO biosynthesis pathway genes genotypes for CHD.
| Genotype |
Phenotype |
Adjusted |
Adjusted |
||
|---|---|---|---|---|---|
| rs2297518 | rs1049255 | Control, n (%) | CHD, n (%) | OR (95% CI)c | P value |
| GG | CC | 251 (46%) | 297 (54%) | 1.0 (reference) | |
| GG | CT or TT | 477 (48%) | 0.95 (0.74–1.20) | 0.647 | |
| GA or AA | CC | 112 (47%) | 125 (53%) | 1.01 (0.72–1.44) | 0.926 |
| GA or AA | CT or TT | 219 (61%) | 142 (39%) | 0.49 (0.38–0.67) | <0.001 |
| rs2297518 | rs841 | ||||
| GG | GG | 333 (51%) | 321 (49%) | 1.0 (reference) | |
| GG | GA or AA | 451 (51%) | 439 (49%) | 1.15 (0.65-1.19) | 0.375 |
| GA or AA | GG | 107 (41%) | 155 (59%) | 1.79 (1.33–2.40) | <0.001 |
| GA or AA | GA or AA | 168 (50%) | 168 (50%) | 1.03 (0.71–1.51) | 0.867 |
Significance of adjusted OR computed with multiple unconditional logistic regression analysis, adjusting for age, body mass index, hypertension, diabetes, hyperlipidemia, smoking status and different populations.